Together, these data provide direct and clear evidence for the role of MYCN and MYCL expression in platinum resistance and suggest that targeting MYCN or MYCL expression will restore platinum sensitivity and be a viable therapeutic approach for the treatment of SCLC. The gene discussed is MYCN; the disease is small cell lung carcinoma.